FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385582671> ?p ?o ?g. }

• W4385582671 abstract "Abstract Background: Melasma is a common dermatosis in both men and women showing varying degrees of success with treatment. Relapse of melasma is high in dark skin types, which necessitates the need for finding a modality of treatment, which not only treats but also prevents relapse. Aims: To study the effectiveness of platelet-rich plasma (PRP) in patients of melasma both clinically and dermoscopically in dark skin types. Materials and Methods: A prospective study of 20 female patients of Fitzpatrick skin type IV–V with mixed type of melasma and bilateral involvement of the face were enrolled for the study. PRP was injected intradermally at 4 weeks interval for three sittings, and the results were assessed clinically (by modified melasma area and severity score) and dermoscopically. Patients were counselled to ensure strict sun protection measures. Patient satisfaction was noted at baseline, 4 weeks, 8 weeks, and 12 weeks. Patients were followed up for 3 months to see for any relapse of the pigmentation. The follow-up showed no relapse of melasma in these patients. Statistical Analysis: Analysis of variance was used with Bonferroni correction for modified melasma area and severity score at various time interval. Subject global aesthetic improvement scale (SGAIS) and physician global esthetic improvement scale (PGAIS) were expressed in counts. P -value ≤ 0.05 was considered significant. Results: Modified melasma area and severity score and dermoscopic changes showed statistically significant improvement compared at the end of study in mild to severe cases. The subjective assessment was made by PGAIS. Patient satisfaction levels (assessed by SGAIS) also showed significant improvement in successive weeks of treatment. Few patients had mild redness and burning post procedure, which resolved spontaneously after few hours. Conclusion: From this study we concluded that PRP shows a significant improvement in melasma after 12 weeks of treatment with no relapse even after 3 months. Hence, PRP may be used not only as an adjuvant but also as a first line treatment in the view of longer sustained results when combined with strict sun protection. There is a paucity of studies showing results of PRP treatment in dark skin types, which is more resistant to treatment than lighter skin. Moreover, clinical improvement should not be the only parameter to decide on stopping treatment as chances of relapse can be higher. Dermoscopic evaluation helps in determining the changes in vasculature (telangiectasias) and pigmentation (dots and globules), which are better indicators of success of treatment." @default.
• W4385582671 created "2023-08-05" @default.
• W4385582671 creator A5014800403 @default.
• W4385582671 creator A5038160493 @default.
• W4385582671 creator A5046261062 @default.
• W4385582671 date "2023-08-04" @default.
• W4385582671 modified "2023-09-24" @default.
• W4385582671 title "Intradermal platelet-rich plasma for the treatment of melasma: A clinical and dermoscopic evaluation in dark skin" @default.
• W4385582671 cites W2107363885 @default.
• W4385582671 cites W2777735664 @default.
• W4385582671 cites W2805825662 @default.
• W4385582671 cites W2892092373 @default.
• W4385582671 cites W2977387290 @default.
• W4385582671 cites W3036740537 @default.
• W4385582671 cites W3044939114 @default.
• W4385582671 cites W3134407405 @default.
• W4385582671 cites W3163670610 @default.
• W4385582671 cites W3182133975 @default.
• W4385582671 cites W3216758556 @default.
• W4385582671 cites W4200111320 @default.
• W4385582671 cites W4211223034 @default.
• W4385582671 doi "https://doi.org/10.4103/jcas.jcas_176_22" @default.
• W4385582671 hasPublicationYear "2023" @default.
• W4385582671 type Work @default.
• W4385582671 citedByCount "0" @default.
• W4385582671 crossrefType "journal-article" @default.
• W4385582671 hasAuthorship W4385582671A5014800403 @default.
• W4385582671 hasAuthorship W4385582671A5038160493 @default.
• W4385582671 hasAuthorship W4385582671A5046261062 @default.
• W4385582671 hasBestOaLocation W43855826711 @default.
• W4385582671 hasConcept C126322002 @default.
• W4385582671 hasConcept C16005928 @default.
• W4385582671 hasConcept C188816634 @default.
• W4385582671 hasConcept C2776677263 @default.
• W4385582671 hasConcept C2778561401 @default.
• W4385582671 hasConcept C2780076745 @default.
• W4385582671 hasConcept C3018082644 @default.
• W4385582671 hasConcept C71924100 @default.
• W4385582671 hasConcept C89560881 @default.
• W4385582671 hasConceptScore W4385582671C126322002 @default.
• W4385582671 hasConceptScore W4385582671C16005928 @default.
• W4385582671 hasConceptScore W4385582671C188816634 @default.
• W4385582671 hasConceptScore W4385582671C2776677263 @default.
• W4385582671 hasConceptScore W4385582671C2778561401 @default.
• W4385582671 hasConceptScore W4385582671C2780076745 @default.
• W4385582671 hasConceptScore W4385582671C3018082644 @default.
• W4385582671 hasConceptScore W4385582671C71924100 @default.
• W4385582671 hasConceptScore W4385582671C89560881 @default.
• W4385582671 hasLocation W43855826711 @default.
• W4385582671 hasOpenAccess W4385582671 @default.
• W4385582671 hasPrimaryLocation W43855826711 @default.
• W4385582671 hasRelatedWork W2110175712 @default.
• W4385582671 hasRelatedWork W2884092690 @default.
• W4385582671 hasRelatedWork W3005103945 @default.
• W4385582671 hasRelatedWork W3166036062 @default.
• W4385582671 hasRelatedWork W3167447492 @default.
• W4385582671 hasRelatedWork W4200111320 @default.
• W4385582671 hasRelatedWork W4284690728 @default.
• W4385582671 hasRelatedWork W4285794454 @default.
• W4385582671 hasRelatedWork W4382981969 @default.
• W4385582671 hasRelatedWork W3029519588 @default.
• W4385582671 isParatext "false" @default.
• W4385582671 isRetracted "false" @default.
• W4385582671 workType "article" @default.